There, Dr. Haas lent her extensive expertise in pharmaceutical strategy, clinical research, and biotechnology to the Keynote Session, What Will be the Impact of Silicon Valley on Drug Development? This panel was moderated by Dr. Reed Tuckson, President of the American Telemedicine Association, an organization whose mission is to promote the improvement in health care delivery through telecommunications and information technology.
Since its first meeting in 2011, the CNS Summit has become the premiere event for those involved in drug development to meet, network, and participate in initiatives that will shape the future of CNS drug development. With a community focus, the CNS Summit is dedicated to encouraging the active participation and collaboration between all stakeholders within a precompetitive space, where practical solutions for advancing CNS drug development can be discussed. In addition to attending Scientific Sessions and Roundtable Discussions, all attendees are encouraged to actively participate in the CNS Summit Work Groups.
The goals of the CNS Summit align closely with those of Cohen Veterans Bioscience, a cooperative research alliance committed to transforming the study of brain disorders and accelerating the discovery of new diagnostics, treatments, and cures. For more details on the CNS Summit and to learn more about their previous meetings, please visit their website.